Predictive Oncology Inc. (AGPU)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
AGPU Chart
Axe Compute Inc. (AGPU) Q1 2026 Earnings Call Prepared Remarks Transcript
Axe Compute Inc. (AGPU) Q1 2026 Earnings Call Prepared Remarks Transcript
Axe Compute Stock Rockets Higher On $260 Million GPU Contract
Axe Compute Inc. (NASDAQ:AGPU) shares are trading higher Wednesday after the company announced it signed a 36-month enterprise infrastructure contract to deliver dedicated GPU compute and AI-focused high-speed storage infrastructure from a single U.S. Tier 3 data center facility.
Axe Compute Inc. (AGPU) Q4 2025 Earnings Call Prepared Remarks Transcript
Axe Compute Inc. (AGPU) Q4 2025 Earnings Call Prepared Remarks Transcript
Predictive Oncology Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $1.62 | $7.11 | $5.49 | 338.89% |
Predictive Oncology Inc. (AGPU) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Predictive Oncology Inc. ever had a stock split?
Predictive Oncology Inc. Profile
| Transportation Infrastructure Industry | Industrials Sector | Christopher Miglino CEO | NASDAQ (NMS) Exchange | 74039M408 CUSIP |
| US Country | 23 Employees | - Last Dividend | 30 Sep 2025 Last Split | - IPO Date |
Overview
Axe Compute Inc. is a knowledge and science-driven company focusing on the application of artificial intelligence (AI) to advance the discovery and development of cancer therapies. Established in 2002 and headquartered in Pittsburgh, Pennsylvania, the company operates primarily through two segments: Pittsburgh and Eagan. The Pittsburgh segment leverages a proprietary biobank containing over 150,000 tumor samples to enhance its AI applications, while also developing proprietary 3D culture models that support drug development initiatives. The Eagan segment specializes in the production of the FDA-cleared STREAMWAY System and related products, which are designed for the automated management of medical fluid waste and streamlined patient-to-drain fluid disposal. In addition, Axe Compute maintains a strategic collaboration with Every Cure to identify and prioritize drugs suitable for repurposing, facilitating progress in oncology research and treatments. The company, originally known as Predictive Oncology Inc., rebranded as Axe Compute Inc. in December 2025.
Products and Services
- AI Applications for Cancer Therapy Development
This service harnesses the power of artificial intelligence to analyze data from its extensive biobank of tumor samples, aiding researchers in uncovering new therapeutic possibilities and enhancing the precision of oncology treatments.
- Proprietary Biobank
Ake Compute Inc. houses a comprehensive biobank of over 150,000 tumor samples, which serves as a critical resource in supporting research initiatives and AI applications for drug development and discovery in oncology.
- 3D Culture Models
The development of proprietary 3D culture models represents a cutting-edge approach in drug testing and development, providing a more accurate representation of human tumor environments and thereby facilitating better therapeutic outcomes.
- STREAMWAY System
This FDA-cleared system is designed for the automated management of medical fluid waste, automating the processes of disposal and enhancing safety and efficiency in medical settings.
- Medical Fluid Disposal Products
Axe Compute offers associated products that support the proper handling and disposal of medical fluids, ensuring compliance with safety regulations and enhancing operational workflows in healthcare facilities.
- Drug Repurposing Collaboration
Through its strategic partnership with Every Cure, Axe Compute aims to identify and reprioritize existing drugs, optimizing their use for new therapeutic applications, particularly in cancer treatment, thereby accelerating the pathway to effective therapies.
